Updates for the treatment of EGPA.

  title={Updates for the treatment of EGPA.},
  author={Lo{\"i}c Raffray and Lo{\"i}c Guillevin},
  journal={Presse medicale},

Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.

The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?

Both clinical features, disease activity, and treatments appear to be significantly different between EGPA subgroups, although the relapse risk was similar although clinical features and treatment strategies were different.

Renal Involvement as Rare Acute Tubulointerstitial Nephritis in a Patient with Eosinophilic Disorder Treated with Early Add-on Administration of Mepolizumab

The revised classification of EGPA based on the etiology should dictate the proper treatment in suspected EGPA patients with nonsystemic vasculitis.

Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.

Mepolizumab 100 mg provided a significant decrease in SNOT-22 values, especially in nasal and sleep domains, eosinophil counts and OCS dose in the 6th month.

Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs

The mechanism of immunosuppressants, new agents' discovery, and current therapeutic protocols in the transplantation are discussed, and the importance of individualized drug use is shown.




Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review

Characteristics of eosinophilic granulomatosis with polyangiitis are reviewed and an overview of established and novel pharmacological agents is provided.

Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

A 16-year-old female patient with severe EGPA (gastrointestinal and cutaneous vasculitis, rhinitis and asthma) refractory to conventional treatment is reported, who was treated with rituximab, which enabled rapid control of the Vasculitis component of the disease, but there was no response to rhinococci and asthma.

Severe bronchospasm associated with rituximab for refractory Churg–Strauss syndrome

Attention is drawn to the potential risk of rituximab-associated bronchospasm, by reporting that therapy-refractory CSS5 was successfully treated with ritUXimab in three patients, and the potential role of B lymphocytes plays a role as antigen-presenting cells and can modulate the immune response in another way than targeting antibody production.

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Preemptive retreatment with RTX, combined with standard maintenance immunosuppressants, resulted in a sustained treatment response and rituximab proved to be an efficient and safe treatment for AN CA-positive and ANCA-negative patients.

Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.

In this pilot study, RTX was safe and successful in controlling renal disease activity in three patients with CSS and deserves further study in CSS.

Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

The treatment of EGPA with rituximab resulted in high rates of improvement and reduced requirement of prednisolone, and may be considered for the treatment ofEGPA.

Churg-Strauss syndrome successfully treated with rituximab

Two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity are described.

Rituximab in Churg-Strauss syndrome

B cell depletion with rituximab has proved effective in autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and antineutrophil cytoplasmic antibody (ANCA) associated vasculitis.